Diane Donegan,Irina Bancos
Diane Donegan
Introduction: Opioid-induced adrenal insufficiency (OIAI) is a known, but often overlooked complication associated with chronic opioid use. It is important to recognize OIAI as, if untreated, can lead to increased morbidi...
Marcel H A Muskiet,David Z I Cherney
Marcel H A Muskiet
Introduction: Chronic kidney disease (CKD) affects ~30-40% of people living with type-1 diabetes (T1D) and remains a major driver of cardiovascular morbidity, kidney-failure, and premature mortality. Despite advances in d...
Resmetirom and semaglutide: next-generation therapies for metabolic-associated steatohepatitis. Opportunities, challenges and issues [0.03%]
新型代谢相关脂肪性肝炎药物树脂托洛和索马鲁肽的研发机遇、挑战与问题
Luigi E Adinolfi,Aldo Marrone,Antonio Izzi et al.
Luigi E Adinolfi et al.
Introduction: Resmetirom and semaglutide are the first drugs to be approved for the pharmacological treatment of metabolic-associated steatohepatitis (MASH) and moderate-to-severe liver fibrosis. However, approval was bas...
Crinecerfont: emerging role in the management of congenital adrenal hyperplasia [0.03%]
康士 Spront：在先天性肾上腺皮质增生症管理中的作用初探
Olga Fedorova,Henrik Falhammar
Olga Fedorova
Introduction: Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is a rare genetic endocrine disorder characterized by impaired cortisol synthesis, excessive adrenal androgen production, and elevated ad...
Improving outcomes through early diagnosis and care in diabetes during pregnancy: are we doing enough? [0.03%]
妊娠期糖尿病的早期诊断和治疗可改善预后——我们做得够了吗？
Annunziata Lapolla,Elisabetta Torlone
Annunziata Lapolla
Introduction: The prevalence of preexisting type 1 and type 2 diabetes in pregnancy continues to rise, with women with type 2 facing adverse maternal and fetal outcomes comparable to those with type 1. Despite internation...
Do women with young-onset type 2 diabetes have a higher risk for adverse pregnancy outcomes? [0.03%]
年轻发病2型糖尿病女性妊娠结局不良的风险较高吗？
Christine P Field,Kartik K Venkatesh
Christine P Field
Resmetirom and semaglutide therapy for patients with MAFLD in the MENA region: expert panel recommendations [0.03%]
针对中东和北非地区MAFLD患者的Resmetirom和Semaglutide治疗：专家小组推荐意见
Yasser Fouad,Khalid M AlNaamani,Fatheya Alawadi et al.
Yasser Fouad et al.
Introduction: Metabolic dysfunction-associated fatty liver disease (MAFLD) affects 25-30% of the global population, with the Middle East and North Africa (MENA) region showing some of the highest prevalence rates, reachin...
The relationship between iron deficiency and thyroid function: findings from a population-based study in Jordan [0.03%]
铁缺乏与甲状腺功能的关系：约旦一项基于人口的调查结果
Nour Abdo,Asma&#x;a Alselwi,Muna Ebbini et al.
Nour Abdo et al.
Background: This study aimed to examine the association between iron deficiency (ID) and thyroid dysfunction among Jordanian adults. Research design and m...
Beyond normalization: rethinking optimal prolactin levels in prolactinoma management [0.03%]
垂体泌乳素瘤管理中最佳泌乳素水平的再思考
Antoni Puzio,Monika Hylinska,Oliwer Kapała et al.
Antoni Puzio et al.
Introduction: Prolactinoma, the most common functioning pituitary tumor, poses ongoing challenges due to variable clinical presentation, treatment resistance, and high recurrence rates. While normalization of prolactin (P...
Surgical considerations for adult Graves' disease: a narrative review of indications, perioperative challenges and postoperative outcomes [0.03%]
成人Graves病手术注意事项：指征、术前术后挑战及结果的叙事性综述
Luigi Bartalena,Daniela Gallo,Eliana Piantanida et al.
Luigi Bartalena et al.
Introduction: Graves' disease (GD) is a systemic autoimmune disorder, ultimately caused by autoantibodies stimulating the TSH receptor (TSHR-Ab) on thyroid follicular cells. Novel targeted therapies are under investigatio...